68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the potential of the 68Ga-NODAGA-RGD for the evaluation of neoangiogenesis in patients followed for a neoplastic pathology and for whom a18F-FDG (or 18F-FET for gliomas) is indicated for initial extension evaluation or suspicion of recurrent tumor.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Lausanne Hospitals
• Collaborator: George Coukos, MD PhD, Head of oncology
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• Age ≤ 85 years old

• Karnofsky index: ≥ 80%

• Patients presenting a neoplasic pathology, histologically proven, known to have expressed integrin αvβ3and for which a 18F-FDG (or a 18F-FETfor glioma) is indicated : (1) glioma (WHO I, II-IV), (2) malignant melanoma, (3) cancer of upper respiratory tract, (4) breast cancer,(5) bone metastasis, (6) ovarian cancer, (7) lung cancer,(8) non-Hodgkinian malignant lymphoma with extra- lymphatic nodes extension, (9) neuroendocrine tumors, (10) pancreatic cancer,(11) oesophagus cancer,(12) stomach cancer. 10 patients will be included per type of cancer.

• Informed consent signed

Exclusion Criteria:

• Incapacity to sign the informed consent

• Pregnancy, breastfeeding

• Age <18 years